MEDICAGO
16.12.2021 20:02:09 CET | Business Wire | Press release
Medicago, a biopharmaceutical company headquartered in Quebec City, is pleased to announce submission of the positive Phase 3 data for regulatory review by Health Canada as part of the New Drug Submission for COVID (NDS-CV) rolling review for Medicago’s COVID-19 vaccine candidate combined with GSK’s pandemic adjuvant. Medicago is seeking review and approval for the vaccine candidate for indication in healthy adults, aged 18 years and above.
“We are pleased to submit our Phase 3 data as the final portion of the rolling submission for our COVID-19 vaccine candidate for review,” said Dr. Judith Atkins, Vice-President of Regulatory Affairs at Medicago. “We are grateful to Health Canada for their review, and we hope this brings Canadians and the world one step closer to having greater vaccine diversity.”
Thomas Breuer, Chief Global Health Officer, GSK, added: “We are one step closer to our goal of making this innovative adjuvanted, plant-based vaccine available. As a refrigerator-stable option that builds on our established adjuvant technology, we are hopeful it will play an important role in the efforts to overcome the COVID-19 pandemic.”
The New Drug Submission for COVID (NDS-CV) process allowed the submission of nonclinical sections, quality, clinical safety, and efficacy information as they became available for Health Canada’s immediate review to accelerate the overall review process. Submitting the Phase 3 data completes the submission process.
The regulatory filing process for the COVID-19 vaccine candidate has been initiated with the FDA (US) and MHRA (UK). Preliminary discussion is underway with the WHO for preparation of the submission. A Phase 1/2 trial has also been initiated in Japan where Medicago plans to submit for regulatory approval in combination with the Phase 2/3 global study results next spring. The vaccine candidate has not yet been approved by any health authorities.
“If authorized, Medicago’s COVID-19 vaccine would be the world’s first ever plant-based vaccine approved for human use,” said Takashi Nagao, CEO and President of Medicago. “It would also be the first Canadian vaccine approved in over 20 years, signaling a powerful step forward for Canada’s vaccine preparedness strategy.”
About Medicago
Medicago is on a mission to help improve global public health using the power of plants. Founded in 1999 with the belief that innovative approaches and rigorous research would bring new solutions in healthcare, Medicago is a pioneer in plant-based therapeutics. We are proudly rooted in Quebec, with manufacturing capacity in both Canada and the US. Our passionate and curious team of over 500 scientific experts and employees are dedicated to using our technology to provide rapid responses to emerging global health challenges, and to advancing therapeutics against life-threatening diseases worldwide. Medicago is an affiliated company of Mitsubishi Tanabe Pharma Corporation. For more information: www.medicago.com
About Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation (MTPC) Group, the majority parent company of Medicago, is one of the large Japanese pharmaceutical companies, with its headquarters in Osaka, Japan. It positions vaccines as one of its key R&D areas under its Medium-Term Management Plan 21-25 and is also working to develop new modalities of vaccines. MTPC Group will further contribute to the prevention of infectious diseases which is one of the world’s important social issues, by delivering a new option of plant-based VLP vaccine as a new type of vaccine. For further information please visit https://www.mt-pharma.co.jp/e/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216005780/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rising Global Bullion Market Risks Are Forcing European Investors to Rethink Physical Gold Access3.2.2026 10:35:00 CET | Press release
As volatility reshapes global financial markets, European institutional investors are turning to safe-haven assets. While physical gold remains one of the world's most resilient and attractive store-of-value assets, secure and verifiable access to bullion has become increasingly difficult. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203826775/en/ Illustrative image of physical gold bullion bars. (Photo: AETOSWire) Recent industry developments have placed structural pressure on the gold market. Elevated price levels have heightened concerns around counterfeit bars, fragmented supply chains, and the complexity of cross-border custody. For European institutions operating under strict regulatory oversight, the challenge is no longer whether to allocate to gold — but how to do so safely, transparently, and within established compliance frameworks. To this end, Golden Ark Reserve, operated by Golden Ark General Trading (FZC)
Hyper-Personalization at Scale: Why Brands Must Shift to an Agentic AI Strategy3.2.2026 10:00:00 CET | Press release
As Infobip celebrates 20 years of customer communication innovation, the AI-first company envisions the future of agentic AI Global AI-first cloud communications platform Infobip, celebrating two decades of innovation, predicts an imminent and seismic shift in brand-consumer engagement. Moving away from the current application-to-person (A2P) messaging, Infobip forecasts a widespread shift to an agent-to-person model, eventually leading to a fully autonomous agent-to-agent future by 2030. The Evolution of Engagement Swift AI adoption is driving enterprises toward agentic AI communication models, which drive autonomous customer communications across all touchpoints. This technology enables hyper-personalization across multiple channels, creating highly engaging content tailored to individual needs. Silvio Kutić, Infobip CEO, comments: “How we communicate with brands is constantly evolving. In this new agentic AI world, brands must seize the opportunity to take a holistic approach to com
Corona Cero Unveils Global Roster of Athlete Ambassadors to Champion TIME CERO at Milano Cortina 20263.2.2026 09:00:00 CET | Press release
A First-of-Its-Kind Initiative, In Partnership with International Olympics Committee (IOC), TIME CERO Empowers Athletes to Unwind, Recharge, and Celebrate the Moment Corona Cero Invites Fans to Celebrate Together in Italy with Corona Hotel, Casa Corona, and Other Immersive Activities Corona Cero today unveiled its global roster of brand ambassadors who will champion TIME CERO, the brand’s new initiative created in partnership with the IOC and Athlete365, throughout the Olympic Winter Games. Together, Team Corona Cero will bring the brand’s “For Every Golden Moment” global platform to life, reminding people that meaningful golden moments can happen anytime, anywhere, or in any season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203205858/en/ Team Corona Cero Central to Corona Cero’s commitment as a Worldwide Olympic Partner, TIME CERO is designed to celebrate Olympians and help them relax, stay present, and embrace bala
Generali Deutschland AG Selects Clearwater Analytics to Modernize and Scale Investment Operations Unit-Linked Fund Business3.2.2026 09:00:00 CET | Press release
Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, announced today that Generali Deutschland AG has selected CWAN’s investment management platform for its €40 billion unit-linked fund (ULF) life insurance business, unifying processes across four subsidiaries and preparing the group for accelerated growth in one of Europe’s fastest-expanding sectors. The partnership reflects a strategic move ahead of unprecedented market expansion. The global unit-linked insurance market reached $906.9 billion in 2023 and is projected to grow at 10.9% annually through 2032, reaching $2.3 trillion, according to Allied Market Research. This growth trajectory is creating competitive separation between insurers capable of scaling operations and those constrained by fragmented systems across multiple European jurisdictions. Under a multi-year agreement, Generali Deutschland will consolidate portfolio management, order execution, and reconciliation on CWAN
Ares Completes Acquisition of BlueCove to Launch Systematic Credit Strategy3.2.2026 09:00:00 CET | Press release
Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today that it has completed its acquisition of all outstanding shares of BlueCove Limited (“BlueCove”), a London-based systematic fixed-income manager. The integrated BlueCove business will operate as Ares Systematic Credit, the latest strategy within the Ares Credit Group. Ares Systematic Credit offers systematic fixed-income strategies that harness the power of data and technology to deliver differentiated solutions to investors. The strategy leverages proprietary technology to support an evidence-based and data-driven investment process across high-yield, investment grade corporates, convertible bonds, and other liquid credit instruments in a variety of portfolio constructions. These methods seek to systematically access, select, analyze and deploy information to capitalize on market inefficiencies and generate high-quality alpha. Led by Alex Khein, most recently CEO of Blue
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom